Leishmania IgG/IgM Rapid Test Device (WB/S/P)

Leishmaniasis is a parasitic disease caused by Leishmania parasites and transmitted through infected sandfly bites. The disease may appear as cutaneous, mucocutaneous, or visceral leishmaniasis. Visceral leishmaniasis, also known as kala-azar, can become severe if not diagnosed and managed properly.

• Rapid antibody screening can help support early detection of suspected leishmaniasis cases.
• Leishmania IgM antibodies may indicate recent or active immune response, while IgG antibodies may suggest past exposure or ongoing immune response.
• Rapid testing may support hospitals, clinics, public health screening programs, travel medicine support, and endemic-area healthcare settings.
• Visceral leishmaniasis symptoms may include prolonged fever, weakness, enlarged spleen or liver, weight loss, and abnormal blood counts.

The Leishmania IgG/IgM Rapid Test Device by LARKSOIS Pharma may be used in professional diagnostic and infectious disease screening environments.

Applications

• Hospitals and clinics
• Diagnostic laboratories
• Fever and infectious disease clinics
• Public health screening programs
• Endemic-region healthcare settings
• Travel medicine support
• Medical procurement agencies
• International diagnostic distributors
• Professional point-of-care testing

• The Leishmania IgG/IgM Rapid Test Device works on lateral flow immunochromatographic assay technology.
• When the specimen is added to the device, it migrates across the membrane by capillary action.
• If Leishmania-specific IgG or IgM antibodies are present, they react with coated recombinant antigens and form visible test lines.
• The test commonly includes an IgM line, IgG line, and a control line to confirm proper test performance.

The Leishmania IgG/IgM Rapid Test Device uses rapid lateral flow immunochromatographic technology for qualitative detection and differentiation of Leishmania IgG and IgM antibodies in whole blood, serum, or plasma specimens.

Benefits

• Detects Leishmania IgG antibodies
• Detects Leishmania IgM antibodies
• Suitable for whole blood, serum, and plasma
• Rapid visual result
• Simple professional testing workflow
• No complex instrument required
• Supports endemic-region screening programs
• Useful for travel-related infectious disease evaluation

The Leishmania IgG/IgM Rapid Test Device supports whole blood, serum, and plasma specimens. This flexibility allows healthcare professionals to use the most appropriate specimen type depending on laboratory workflow and clinical setting.

Guidance

• Use approved whole blood, serum, or plasma specimens only
• Collect specimens according to the product insert
• Use clean and suitable sample collection materials
• Avoid contaminated or improperly stored samples
• Apply the specimen correctly to the test device
• Read results only within the recommended time window
• Handle all specimens according to laboratory safety procedures
• Follow the official testing protocol carefully

Note

Specimen collection, testing, timing, and storage should always follow the official LARKSOIS Pharma kit insert.

The Leishmania IgG/IgM Rapid Test Device by LARKSOIS Pharma is designed for qualitative detection and differentiation of Leishmania IgG and IgM antibodies in whole blood, serum, or plasma specimens. Many Leishmania rapid tests use recombinant antigens such as rK39 for visceral leishmaniasis antibody screening.

• An IgM-positive result may suggest recent or active immune response.
• An IgG-positive result may indicate past exposure, later-stage infection, or ongoing immune response.
• A negative result does not completely rule out infection, especially in early disease stages or low antibody conditions.
• Diagnosis of leishmaniasis may also involve microscopy, PCR, tissue testing, culture, and serology depending on disease type and clinical context.

The Leishmania IgG/IgM Rapid Test Device is a professional screening aid and should not be used as the only basis for diagnosis. Antibody-based testing may have limitations depending on disease type, immune response, and clinical stage.

Instructions

• For professional in-vitro diagnostic use only
• Use approved specimens only
• Improper specimen handling may affect results
• False positive or false negative results may occur
• Cross-reactivity may occur in some situations
• Clinical evaluation and confirmatory testing may be required
• Read results only within the recommended time
• Follow the official product insert carefully

Instructions

• Detects Leishmania IgG antibodies
• Detects Leishmania IgM antibodies
• Suitable for whole blood, serum, and plasma
• Rapid visual result
• Simple test procedure
• No complex instrument required
• Supports endemic-region screening programs
• Suitable for international diagnostic supply

Note

The Leishmania IgG/IgM Rapid Test Device by LARKSOIS Pharma is designed for practical, rapid, and accessible infectious disease antibody screening support.

Steps

• Bring the test device, specimen, and buffer to room temperature
• Open the sealed pouch only when ready to test
• Place the test cassette on a clean and flat surface
• Add whole blood, serum, or plasma to the sample well
• Add buffer according to the instructions for use
• Wait for the recommended reaction time
• Read the IgG, IgM, and control lines within the valid time window
• Do not interpret results after the recommended reading time
• Dispose of used materials according to laboratory safety procedures

Note

Testing should be performed by trained healthcare professionals according to the official LARKSOIS Pharma product insert.

Positive

An IgM-positive result may suggest recent or active immune response. An IgG-positive result may indicate past exposure, ongoing infection, or later-stage immune response.

Negative

A negative result means Leishmania IgG/IgM antibodies were not detected at the test’s detectable level. Early infection or low antibody levels may still require further testing.

Invalid

If the control line does not appear, the test result is invalid. Testing should be repeated with a fresh device.

Instructions

• Store the Leishmania IgG/IgM Rapid Test Device according to the product label and insert
• Store in a cool and dry place
• Keep sealed until use
• Protect from heat, sunlight, and moisture
• Do not freeze unless specified
• Do not use expired kits
• Use immediately after opening the pouch
• Follow all instructions for use carefully

Instructions

• For professional in-vitro diagnostic use only
• Handle all specimens carefully
• Wear gloves and protective equipment during testing
• Do not reuse the test cassette
• Avoid specimen contamination
• Do not use damaged or expired kits
• Read results only within the recommended time
• Interpret results with clinical findings and exposure history

LARKSOIS Pharma provides internationally suitable diagnostic products for hospitals, laboratories, clinics, healthcare procurement agencies, distributors, and public health programs. The Leishmania IgG/IgM Rapid Test Device is designed for fast, practical, and accessible antibody screening support.

Advantages

• International infectious disease rapid test portfolio
• Reliable Leishmania antibody screening support
• Suitable for hospitals, clinics, and laboratories
• Distributor-friendly product support
• Professional healthcare quality standards
• Practical point-of-care diagnostic format
• Accessible infectious disease screening solution